Pfizer Trims Altana From Pipeline

On July 1 Pfizer Inc. announced it was discontinuing development of Phase III COPD drug roflumilast (Daxas) and of Phase IIb HIV/AIDS drug capravirine, due to disappointing clinical results. The roflumilast decision highlights Pfizer's changing requirements and circumstances, as well as originator Altana's dependence on the compound.